Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Case 1 Male patient died while receiving semaglutide report invalidated because call-center contractors claimed patient identifier was missing (FDA found it in source documents) Case 2 Consumer taking liraglutide suffered a disabling stroke report cancelled because the consumer said it was unrelated to the drug Case 3 Patient taking semaglutide became depressed and committed suicide no follow-up attempts documented, still not submitted to FDA as of March 2026 Case 4 Consumer reported suicidal ideation on semaglutide in December 2024 not reviewed until February 2025, only after FDA inspectors flagged it Case 5 FDA found Novo Nordisk's written procedures allowed adverse events to be rejected based on causality assessments contradicting federal reporting requirements A Second Front: Vision Loss Claims Beyond the GI injury cases, a second GLP-1 MDL was created in December 2025 for vision loss claims
Incorporate Strength Training Resistance training at least 34 times per week can help preserve muscle mass
GLP-1 drugs are here to stay Like any potent medication, GLP-1 drugs come with controversy
04 Swirl, don't shake Gently roll until fully dissolved
US$ 29.61
US$ 27.58
US$ 21.17
US$ 29.44
US$ 20.30
